Key Highlights

  • Cypherpunk Technologies (NASDAQ:CYPH) held about 323,394 ZEC as of August 11, 2026, bought at an average price of USD 341.83 per coin, according to its second quarter report.
  • Published market data showed the Penny Stock near USD 2.90, up 11.54% on Volume of about 11.48 million shares, though the snapshot date is not shown and these figures are unconfirmed.
  • Second quarter Net Income was USD 39.4 million, or USD 0.18 per diluted share, against a loss of USD 16.6 million a year earlier, mainly on a USD 46.0 million unrealized gain on ZEC.
  • Cash and equivalents stood at USD 7.6 million on June 30, 2026, while general and administrative expense rose to USD 4.5 million from USD 1.8 million a year earlier.

A Biotech Shell Turned ZCash Treasury Vehicle

Cypherpunk Technologies, formerly the cancer drug developer Leap Therapeutics, now describes itself as a privacy technology company that accumulates the Zcash token (ZEC) and invests in privacy technologies. Cypherpunk Technologies (NASDAQ:CYPH) still owns a drug subsidiary, Leap, which reached agreement with the FDA on a randomized Phase 3 trial of sirexatamab in second-line metastatic colorectal cancer, expected to enroll about 270 patients. The company is also running a strategic process to decide the future of that program. In an April 16, 2026 release it reported 303,906.40 ZEC, equal to 1.82% of the network, and said routine holdings updates would move to its website and filings.

Mark-to-Market Profit Explains the Quarter

The second quarter swing to profit came from accounting rather than operations. The company attributed it mainly to a USD 46.0 million unrealized gain on its ZEC treasury, with the holdings valued at about USD 129.4 million on June 30, 2026 at a ZEC price of USD 400.09. Research and Development spending fell to USD 0.2 million from USD 10.5 million as the drug work wound down. Because the coin is carried at market value, a decline in ZEC would flow straight into reported results in the opposite direction. The average purchase price of USD 341.83 per coin sits below the June 30 price of USD 400.09, which is why the holdings showed an unrealized gain.

Thin Trading Risk Around a Penny Stock

Shares priced at USD 5 or less are classed here as a penny stock, and a small number of trades can move the price. Spreads can be wide, quoted moves can reverse quickly, and a gain on heavy volume does not imply any continuation. Cash of USD 7.6 million is small beside a treasury that can swing by tens of millions of dollars with the coin. Investors may watch the next quarterly report, any change in ZEC holdings posted on the company website, and news on the sirexatamab strategic process.

Where Things Stand

Cypherpunk Technologies (NASDAQ:CYPH) ended up holding 323,394 Zcash because a former biotech redirected its cash and Capital into buying ZEC, building a stake near 2% of the network by its own reports. The profit it posted for the second quarter is a mark-to-market gain, so the Equity now behaves much like a leveraged proxy for one volatile token plus a small drug subsidiary. The penny stock label matters: Liquidity is thin, and the screen move of 11.54% could not be tied to a confirmed catalyst. The next checkpoints are the third quarter filing and any holdings update.